Biotech and Pharma Industry News | BioPharma Dive
WEBCell and gene therapy investment, once booming, is now in a slump. Far fewer venture funding rounds were closed by cell and gene therapy developers over the first six months of 2024 than in prior years. Experts say there are several factors. BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives.
Biotech M&A is on the upswing. Here are the latest deals.
WEBAug 13, 2024 · BioPharma Dive is tracking M&A activity below. The database, which shows drugmaker buyouts that have happened since 2018 and were valued at $50 million or more in upfront consideration, will be regularly updated. Click on an acquiring company to pull up more information, and scroll to the bottom of the page to read how this information was ...
Lilly wins FDA approval for new kind of diabetes drug
WEBMay 13, 2022 · The Food and Drug Administration on Friday approved Eli Lilly’s diabetes drug Mounjaro, a first-of-its-kind treatment that can help control patients’ blood sugar and, potentially, help them lose weight as well. Mounjaro, also known as tirzepatide, expands Lilly’s diabetes business, which includes insulins as well as other types of therapies.
Amgen bets almost $4B on a biotech and its inflammation drugs
WEBAug 4, 2022 · Amgen bets almost $4B on a biotech and its inflammation drugs. Amgen plans to acquire a fellow Californian biotechnology company, ChemoCentryx, for $3.7 billion in a deal meant to deepen its pool of medicines targeting inflammation and the kidneys. The companies expect their deal, announced Thursday, to close sometime between October and December.
CDC panel mulls changes to RSV vaccine recommendation
WEBMar 1, 2024 · Inside the market of emerging biotech. Currently, the CDC recommends adults 60 years or older discuss RSV vaccination with their physician — a process known as “shared clinical decisionmaking.”. Advisers debated whether, for some individuals at higher risk, a universal recommendation would be more appropriate.
Intarcia’s diabetes drug-device combo voted down again by FDA …
WEBSep 21, 2023 · A Food and Drug Administration advisory committee voted unanimously on Thursday afternoon to reject an appeal for Intarcia Therapeutics’ Type 2 diabetes drug-device combination treatment, citing continued safety concerns. The biotechnology company, which recently morphed into morphed into i2o Therapeutics and pulled in $46 million in funding ...
Gilead forges closer ties with Galapagos in $5.1B deal
WEBJul 14, 2019 · Dive Brief: Gilead will pay $5.1 billion to greatly deepen research ties with Belgian drugmaker Galapagos, announcing Sunday a 10-year deal that ups its ownership stake in the biotech and secures access to a pipeline of experimental drugs targeting inflammation and fibrosis. Gilead head Daniel O'Day, eschewing major M&A in his first major development deal as chief executive, opted for a ...
Horizon acquires Viela Bio for $3B in a windfall for AstraZeneca
WEBFeb 1, 2021 · Horizon Therapeutics has agreed to acquire Viela Bio, a spinout of AstraZeneca, in a deal that values the Maryland-based biotech at roughly $3 billion. Horizon will pay $53 per share for Viela, which in June won U.S. approval for Uplizna, a treatment for the rare autoimmune disease neuromyelitis optica spectrum disorder, or NMOSD.
Merck wins FDA OK for vaccine rival to Pfizer’s pneumococcal shot
WEBJun 18, 2024 · Dive Brief: The Food and Drug Administration on Monday approved a new vaccine from Merck & Co. that protects against 21 types of the bacteria that causes pneumococcal disease. The vaccine, cleared for use in adults 18 and older, will be sold by Merck as Capvaxive. Pneumococcal disease can lead to severe infection in the lungs or sometimes in ...
Biotech IPOs are the industry’s lifeblood. Track how they’re …
WEB2 days ago · IPO activity reached a peak in 2021, when more than 100 biotechs priced an initial offering and together raised nearly $15 billion. But that momentum came to a halt as 2021 turned to 2022, and stock prices of newly public companies plummeted amid a sector-wide downturn. The pace of IPOs stalled and, last year, only 19 drugmakers priced initial ...